Researchers are reporting that a new vaccine designed to treat breast cancer appears to be safe in women with advanced disease. It showed signs of slowing down tumor growth too.

The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast cancer, which affects 20 to 30 percent of breast cancer patients. Using immune cells from a cancer patient's own body, Neuvenge is a tailor-made therapy.

Reports about Neuvenge, published in the Journal of Clinical Oncology, indicate the vaccine did not cause any serious side effects and of the 18 women who participated in the Phase I study, there was a reduction in the size of a tumor in one patient. In three other women, the disease seemed to stabilize for as long as a year.

Cancer drug Gleevec, used for the treatment of chronic myeloid leukemia (CML), has been pulled out of another round of testing so it can get to work stopping the return of a rare stomach cancer. It's that good, according to findings announced on Thursday.

The promise of Gleevec should make it standard treatment for people with gastrointestinal stromal tumors (GIST), a stomach and intestine cancer diagnosed in 5,000 to 6,000 Americans each year.

The drug has already been used for patients whose disease is too advanced for surgery. Now it will be used for those whose tumors can be removed. The drug will be administered for at least one year post-surgery.

More than 600 people participated in this Gleevec trial. Each person took either Gleevec or a sugar pill for one year after surgery. After the one-year mark, cancer returned in 17 percent of people taking the sugar pill and in 3 percent of people taking the actual drug.

Since 50 to 90 percent of GIST cases recur over time, this is great news, say researchers who call Gleevec a highly targeted cancer drug with few side effects.

Research indicates that young breast cancer survivors have a harder time recovering emotionally from cancer than women who develop the disease later in life.

In Australia, a quality of life survey including 300 women found most survivors adjusted normally within 18 months after diagnosis. But women under the age of 50 reported more of a struggle with their emotional health.

Perhaps it's the direct threat to her life, or her fertility, or her sexuality, or her body image that brings on the added challenge for a young woman. Regardless, there are no easy solutions or quick remedies for lightening the load that weighs heavily on young minds.

Breast cancer changes everything, and bouncing back from the disease takes time. And this research validates the need for programs targeted at younger women, as well as further research to more clearly identify how to better help breast cancer's youngest victims.

A little bit of education goes a long way, especially in the war against cancer. Armed with facts and figures and know-how, we can help advance prevention and early detection of this deadly disease.

So in the spirit of National Colorectal Cancer Awareness Month, here are seven truths that serve to broaden your horizons about the third most common cancer found in men and women in this country.

As you read these truths, be aware that the death rate from colorectal cancer has been on a downward climb for the past 15 years due to better screening, fewer diagnosed cases, early detection, and more advanced treatment. Keep in mind that you can help keep this trend going by raising your own awareness and by taking action on behalf of yourself and your loved ones.

• Colorectal cancer refers to cancer that starts in the colon or rectum. These cancers begin in the digestive system where food is processed to create energy and rid the body of solid waste matter.

• Colorectal cancers develop slowly over a period of years and mostly begin in the form of polyps -- growths of tissue that start in the lining and grow into the center of the colon or rectum. Removing polyps early may prevent them from becoming cancerous. More than 95 percent of colon and rectal cancers are called adenocarcinomas.

• For people of average risk, screening is recommended beginning at age 50. Those whose risk is higher than average should talk with a physician about appropriate screening.

• Screening is used to detect disease in people who do not have any symptoms. In many cases, screening tests find colorectal cancers at an early stage and greatly improve the chances of successful treatment. Screening tests can prevent some cancers by allowing doctors to find and remove polyps that might become cancer. There are several tests used to look for colorectal cancer. Ask your doctor what test is best for you.

• Treatment for colorectal cancer includes surgery, radiation therapy, chemotherapy, and newer targeted therapies.

• The American Cancer Society predicts there will be 112,340 new cases of colon cancer and 41,420 new cases of rectal cancer in 2007 in the United States. Combined, the diseases will cause about 52,180 deaths.

• The Colorectal Cancer Coalition -- or C3 -- is a national organization whose mission is to eliminate suffering and death due to colon and rectal cancer through advocacy. Visit here for more information.

The material shared in this post was gathered from the websites of the American Cancer Society and the Colorectal Cancer Coalition.

A study appearing in the Journal of Clinical Oncology reveals there may be something out there that can extend the lives of patients with recurrent prostate cancer.

This something is a new class of anti-cancer targeted drugs that scientists at Cedars-Sinai Medical Center in Los Angeles say are quite promising, despite their ineffectiveness in some prostate cancer patients with no previous chemotherapy treatment.

Pertuzumab, a molecular targeted compound that has been used successfully in ovarian cancer patients, has been shown to block the human epidermal growth factor receptor family by binding to and inhibiting the function of HER2 receptors. They essentially block a key pathway that leads to cancer growth. And this blockage can possibly offer a better, longer life for recurrent prostate cancer patients whose diseases no longer respond to traditional chemotherapy.

Pertuzumab, marketed under the brand name Omnitarg by Roche and Genentech, is just one of many targeted cancer therapies that give researchers hope that cancer may one day be a lifetime disease that can be skillfully managed.

Scientists have uncovered a gene they say may be cancer's master switch.

Like a circuit breast of sorts, the newly identified gene, CHD5, has an important job -- it's a tumor suppressor that prevents cancer from developing. But when it slacks on its job, cells begin to misbehave and tumors can form.

One professor of genetics says the gene, located on chromosome 1, governs the activity of a wide array of other genes involved in tumor-suppression. Its reach is large. And the implications of improper functioning are significant.

Cancers associated with the malfunctioning gene include brain tumors such as gliomas and breast, ovarian, prostate, and colorectal cancers.

A lot of people have been looking for this gene for decades. And now that it's been located, it will influence cancer research for years to come. The discovery will provide valuable new insight into targeted drugs and diagnostics and will turn up patients who need more aggressive treatment.

"We are really excited about our discovery," says the lead investigator of the research, which is published in the journal Nature.

If the experimental breast cancer drug Tykerb continues to prove successful in study participants, it could be headed for FDA approval.

Tykerb, now in international study, showed in early studies to be even more effective and to have fewer side effects than similar breast cancer drug Herceptin. Both drugs are part of a cluster of targeted therapies that attack cancer cells while sparing healthy cells. Designed for use on women whose breast cancer is HER2 positive -- meaning it contains too much of an aggressive protein -- Tykerb may be a wonder drug, with the capability of effectively keeping breast cancer at bay.

Dr. Paul Goss of MA General Hospital says, "We're seeing Tykerb, which is a pill, which is easier to take, has a broader attack and gets inside cells. It's like an electrical circuit that's turned on, and Tykerb can pull the lever, the circuit breaker, and switch it off."

Scientists from Harvard University and Massachusetts Institute of Technology (MIT) are developing a tiny implant that will allow doctors to see what's happening with tumors from the inside out.

If all proceeds according to plan, doctors will one day be implanting tiny sensors inside tumors to determine whether or not cancer drugs are shrinking the tumors. The sensors will also determine whether or not tumors are growing.

Cancer specialists have long wished for better methods of measuring the success of drugs. While blood tests can show if a drug has reached the bloodstream, they don't reveal much about the tumor itself. This small silicone cube, no bigger than two millimeters on each side and embedded in a tumor or lymph node, would remain in the body throughout treatment while essentially broadcasting what's going on inside the tumor.

MIT scientists hope to begin animal experiments within months. Their goal is to one day make the implant as thin as the pieces of led used in mechanical pencils.

This research, funded by the National Cancer Institute, is part of a long-term project to make medical technologies that will cure cancer. It's all part of journey toward complete targeted cancer treatment. And this little implant will have the power to communicate whether or not these treatments are working.

Dr. Len Lichtenfeld, MD, is the deputy chief medical officer for the American Cancer Society. He is also a blogger and authors his very own blog -- called Dr. Len's Cancer Blog.

Dr. Len writes on his blog about all sorts of topics related to cancer. He shares his opinion on the recent drop in breast cancer cases (December 15, 2006), he promotes the Great American Smokeout (November 14, 2006), he sounds off on lung cancer screenings (October 25, 2006), and he urges parents to always slather sunscreen on their children (October 5, 2006). He has so much more to say -- and his blog is a great stop for those wishing for more information on hot cancer topics.

As this year comes to a close, Dr. Len offers a review of what he believes were the hottest cancer topics of 2006.

Dr. Len reflects in his blog about decreased cancer death rates that represent real progress in the fight against cancer. He calls the HPV vaccine a breakthrough and he recaps the STAR trial -- a comparison of raloxifene to tamoxifen to reduce the risk of recurrent breast cancer in post-menopausal women -- with emphasis on how raloxifene proved just as effective as tamoxifen, but with a better safety profile. He calls new targeted therapies a dream -- with a hefty price tag -- sure to garner debate and discussion in 2007.

Dr. Len reviews the Surgeon General's report on second-hand smoke -- it's harmful to non-smokers, the report says -- and he marvels at the capability of science to approach an understanding of what makes a cancer cell a cancer cell. He also remarks on how remarkable it is that chronic myelogenous leukemia is in fact chronic and no longer fatal, thanks to the drug Gleevec.

Of course, there is ample attention given to the declining incidence of breast cancer, reportedly due to less women using hormone replacement therapy, and the risks weighing on those who are overweight and obese, and survivors and supporters who gathered for Celebration on the Hill -- the site of one incredible American Cancer Society event.

Dr. Len closes his review of 2006 with recognition of three celebrities who lost their lives this year to cancer -- Dana Reeve, Ann Richards, and Ed Bradley. And while he recognizes there are other lives and other stories that deserve mention, there is simply not enough time or space for him to do justice to every noteworthy item.

"What we have seen over the past year is an incredible leap forward in cancer research, diagnosis and treatment, and I suspect there are going to be even more exciting developments in the coming year," says Dr. Len who looks forward to 2007 -- a year that is sure to deliver more hope and more progress in the fight against cancer.

Catherine Jones has breast cancer. And she needs Herceptin in order to fight for her life. But Herceptin, a targeted drug used to treat HER2 positive breast cancer, is very expensive -- and for some time, Jones was not sure how she could possibly pay for this potentially life-saving therapy.

Jones, 49 and a resident of New Plymouth, New Zealand, decided to ask for help. So she set up the Herceptin for Catherine Trust to raise the $80,000 needed for the treatment. In less than four weeks, she received $64,600 in donations.

Jones is overwhelmed by the support and says she will continue to use the trust to raise funds -- not just for herself, but for other women in need.

The New Zealand government and its drug-buying agency Pharmac does not fund Herceptin. So most breast cancer patients who medically qualify for the treatment have no means of receiving it.

Jones, who is about to receive her third of 17 Herceptin doses, thinks she can help. She is surely off to a great start.

The combination of breast cancer drugs Tykerb and Xeloda are effective at slowing the progression of metastatic breast cancer after the drug Herceptin fails -- but the drug duo is only effective at extending the lives of patients for a few months, according to the results of a recent international clinical trial.

The trial, led by Charles E. Geyer, M.D., of Allegheny General Hospital, Pittsburgh and published in the December 28 issue of The New England Journal of Medicine, focused on 324 women whose breast cancer had spread to other organs. The women had already been treated with Herceptin for a median of 42-44 weeks -- and then half received Xeloda chemotherapy and half received both Xeloda and Tykerb.

Women who received the drug combination had more than a 50 percent delay in disease progression. Their cancer spread after a median 8.4 months, compared to 4.4 months for women who received only Xeloda.

Targeted drugs Herceptin and Tykerb are major advances in the fight against breast cancer -- for the 20 percent of diagnosed women with the aggressive HER2 positive disease -- and they are also quite expensive. While some say they are worth every penny if they offer a cure, others question the cost if they only delay the disease progression for a few months. Such was the case in this study.

Perhaps the greatest potential for these agents is for use before breast cancer spreads, when they may improve the chance for a cure.

Aspirin, and other nonsteroidal anti-inflammatory drugs (NSAIDs), are known to halt the growth of some cancers, such as colorectal cancer, breast cancer and ovarian cancer, but no one could really explain why. Obviously, as a result it was believed that chronic inflammation might be leading to increased cancer risks. Still, no one could explain how any of this was happening enough to harness the ability to replicate it.

Beth Israel Deaconess Medical Center and Columbia University Medical Center researchers have announced the discovery of a novel tumor suppressor gene that works with NSAIDS to stop the growth of cancer cells.

"Current clinical trials are evaluating a range of NSAIDs for a variety of cancers without any clear vision of the best way to use them," states Towia Libermann, PhD, Director of the BIDMC Genomics Center and Associate Professor of Medicine at Harvard Medical School. "The fact that upregulation of this single gene MDA-7/IL-24 -- correlated not only with cell death induction of numerous types of cancer but also among various diverse classes of NSAIDs, makes this discovery particularly exciting."

As a result of this discovery, researchers believe newer targeted cancer therapies can be developed. To read more about the discovery, visit Beth Israel Deaconess Medical Center and Columbia University Medical Center's Study Explains How NSAIDs Halt Cancer Growth.

Some of the previous posts we have on inflammation, cancer and aspirin are:

• Aspirin: amazing wonder drug in fighting cancer
• Inflammation link between rheumatoid arthritis and cancer
• What aspirin reveals about cancer

In a Phase III trial involving 878 lung cancer patients, the drug bevacizumab, known as Avastin, increased the overall survival rate to 35 percent when combined with the chemotherapy drugs paclitaxel and carboplatin. Patients who were given paclitaxel and carboplatin without Avastin had a 15 percent chance of responding to treatment.

Two months ago, the Food and Drug Administration approved Avastin as a first-line treatment for patients with inoperable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer. Avastin works by stopping the formation of blood vessels that feed oxygen and nutrients needed for tumor growth. Because the drug is a targeted therapy, in that it leaves healthy tissue alone while going after cancer cells, some of the traditional side-effects from conventional chemotherapy, such as hair loss, nausea, or vomiting, are avoided.

According to Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Chief of Hematology/Oncology's Dr. Joan Schiller, "Twenty years ago, we thought no treatment could help patients with advanced lung cancer. Ten years ago, we found that chemotherapy could improve survival of these patients. Now, we are finding out that this very unique drug called Avastin can also help improve survival even more. Avastin is the first of this very exciting family of drugs to be approved for lung cancer, and there are several other drugs of this type under development which may prove to work even better."

At one time, patients with blood cancers were treated with harsh drugs, like interferon or hydroxyurea, yet only two to three percent would ever achieve any sort of remission. Many would suffer such extreme side effects from these drugs they would stop taking the medication early, decreasing even further their potential odds for survival.

The fate of these patients is changing. And the proof is in print -- in today's issue of the New England Journal of Medicine.

It all began with the study of a highly targeted molecular therapy called STI571 -- designed to block the genetic aberration that gives rise to chronic myeloid leukemia (CML), a disease that affects about 6,000 Americans every year. A clinical trial followed, and a compound marketed by the drug company Novartis emerged. Today, this compound is know as Gleevec.

In the clinical trial of Gleevec, 1,106 CML patients were randomly chosen to receive either Gleevec or Interferon. Early results were so encouraging that all but three percent of the participants using Interferon switched to Gleevec. Five-year survival rates were 89 percent. And 93 percent of patients saw no progression to the acute phase of the disease. Many patients witnessed their blood counts return to normal, and a large number experienced a reverse in the gene mutation that causes CML. Virtually no one reported side effects while using the drug.

Despite a rare reaction that can cause heart failure, Gleevec has now been approved by the FDA for the treatment of six other rare, life-threatening disorders. And other drugs similar in nature to Gleevec are hitting the scene. Some believe long-term suppression of CML will come from a cocktail of these types of drugs.

For now, Gleevec -- on its own -- is a success story.

North Carolina State women's basketball coach Kay Yow will soon take a leave of absence so she can fight breast cancer -- for the third time.

Yow, 64, was first diagnosed with breast cancer in 1987. The cancer returned two years ago, and she was treated with hormone therapy and radiation. Just recently, doctors discovered the cancer was progressing. And they have already started treatment with chemotherapy and new targeted biologic therapies.

This is Yow's 32nd season as the head coach of the Wolfpack women's team. Inducted into the Basketball Hall of Fame in 2001, Yow also coached the U.S. women's team in the 1988 Seoul Olympics. The team took home the gold medal.

Associate head coach Stephanie Glance will serve as interim coach while Yow takes on her cancer opponent. "I have every confidence in my coaching staff to continue the development of this outstanding group of young women," Yow said.